Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI – Get Rating) – Stock analysts at Cantor Fitzgerald issued their FY2023 earnings estimates for Spectrum Pharmaceuticals in a research report issued on Monday, June 6th. Cantor Fitzgerald analyst forecasts that the biotechnology company will post earnings per share of ($0.18) for the year. Cantor Fitzgerald has a “Neutral” rating on the stock.
Spectrum Pharmaceuticals (NASDAQ:SPPI – Get Rating) last released its quarterly earnings results on Thursday, March 17th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). During the same quarter in the previous year, the firm posted ($0.36) EPS.
SPPI opened at $0.89 on Wednesday. The company has a fifty day moving average price of $0.91 and a 200-day moving average price of $1.04. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.38 and a current ratio of 2.38. Spectrum Pharmaceuticals has a one year low of $0.60 and a one year high of $4.54.
A number of institutional investors have recently bought and sold shares of SPPI. Moors & Cabot Inc. bought a new position in shares of Spectrum Pharmaceuticals during the third quarter valued at about $26,000. Mirabella Financial Services LLP bought a new position in Spectrum Pharmaceuticals in the first quarter worth about $27,000. Janus Henderson Group PLC bought a new position in Spectrum Pharmaceuticals in the third quarter worth about $34,000. WINTON GROUP Ltd bought a new position in Spectrum Pharmaceuticals in the first quarter worth about $35,000. Finally, Acadian Asset Management LLC bought a new position in Spectrum Pharmaceuticals in the fourth quarter worth about $36,000. 58.51% of the stock is owned by institutional investors and hedge funds.
Spectrum Pharmaceuticals Company Profile (Get Rating)
Spectrum Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma.
- Get a free copy of the StockNews.com research report on Spectrum Pharmaceuticals (SPPI)
- Heavy Buying Points to Upside for These 3 Stocks
- 3 Intriguing Stocks With Sub-10 P/E Ratios
- Time to Buy Take-Two Interactive Stock
- Snap Inc: Revised Guidance & Steeping Losses
- 3 Software Plays Showing Signs of Recovery
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.